Despite the published results and the improvement of forecasts, The actions of Eli Lilly have begun this Thursday session with falls greater than 13% after making known the results of an essay to evaluate the orforglipron, the treatment of oral administration to combat obesity and overweight in adults and without diabetes.
As indicated by the company, at 72 weeks, the three doses of orforglipron fulfilled the main assessment criteria and all key secondary assessment criteria compared to placebo, achieving a clinically significant weight loss as a complement to a healthy diet and physical activity.
Specifically, for the main assessment criteria, orforglipron 36 mg, administered once a day No food restrictions or waterreduced the weight in an average of the 12.4% compared to the 0.9% with placebo.
“With Orforglipron, we work to transform the treatment of obesity through the introduction of a possible oral therapy of a single daily administration that could favor early intervention and long -term management of the disease, while offering a practical alternative to injectable treatments,” said Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health.
In this sense, after “these positive data”, the Lilly manager announced that the company will present Orforglipron for its regulatory review before the end of the year, adding that the pharmacist is prepared for a global launch.
ELI LILY STUDIES RESULTS
Eli Lilly said his experimental pill of LPG-1 He helped patients lose 12.4% of their body weight after 72 weeks in an advanced phase study, below the results of previous trials of the injection -in -law against obesity Wegovy, of Novo Nordisk.
David Ricks said at a conference with investors that “these results encourage us” and added that the company’s goal had always been to offer a powerful GLP-1 medication in a comfortable compressed of a daily shot that could be manufactured more easily.
“We believe that this can have a significant impact on human health and we will urgently work to present orforglipron worldwide to deal with Global Obesity Challenge“, said.
Unlike injectable medications against obesity, which are peptides designed forTo imitate the GLP-1 hormonethat controls the appetite, the orforglipron is a smaller molecule tablet to manufacture and package, according to Kenneth CusterPresident of the Lilly Cardiometabolic Health Division.
Lilly, whose GLP-1 zepbound injectable competes directly with Wegovy, considers that the tablet of a daily shot is a promising alternative to injections That it could be used for early intervention and long -term treatment of the disease, said Custer.
Patient preference too Leads for oral medications in front of injections. Several studies have shown that a significant part of patients prefers pills for comfort and aversion to needles.
“Have great aspirations As for the number of patients who could help orforglipron, “he said about the pill that is taken once a day.
In the study of more than 3,000 people adults overweight or obesity and health problems related to weight, but not with diabetes, which received the highest dose of 36 milligrams of orforglipron lost an average of 12.4% of its weight, compared to 0.9% of those who received a placebo. The patients who received the dose of 6 mg of the drug from Lilly they lost a 7.8% of its weight.
According to Emily Field, Barclays analyst, After the first results of the trials, the drug was expected to be better than Wegovy, of Novo. “It’s worse than Wegovy, so it’s a shock,” he said.
The nausea rate of patients with high doses was 33.7%, while the 24% experienced vomiting, in front of the 10.4% and 3.5%respectively, of the placebo group.
Best stage for Novo
At least two analysts affirmed that the tolerability profile of the orforglipron was not as good as the one observed in an essay that tested the drug in diabetic patients.
Although we continue to consider it manageable, “Nausea and vomiting rates can be higher than investors’ expectations”he said Evan SeigermanBMO Markets BMO Analyst.
Something more than 10% of patients with high doses abandoned the trial due to adverse side effects. According to Lilly, no hepatic security problems were observed.
At least three analysts affirmed that the market expected the orforglipron to equal the weight loss of the 14.9% in 68 Wegovy weeks, as demonstrated in a 2021 essay, and some expected the pill to exceed the popular Novo drug.
Markus Manns, a shareholder of Novo and Lilly, described the results as the best possible scenario for Novo. “Lilly’s competitive threat is suddenly weaker than expected.”
Zepbound and Wegovy currently dominate the weight loss marketwhich according to some analysts will reach US $ 150,000 million in the early 2030s.
The United States Food and Medicines Administration He is studying an oral version of high dose of Wegovy for possible approval at the end of this year. Novo said he helped obese or overweight adults to lose the 15% of your body weight In an advanced phase trial.
According to Lilly, the orforglipron also reduced the risk markers of heart disease, such as cholesterol, triglycerides and blood pressure, in all doses.
Wegovy has been approved to reduce the risk of serious heart problems, and Lilly published last week that demonstrate the cardioprotective qualities of the Mounjaro diabetes treatment, which has the same main ingredient as Zepbound.
Approves for heart disease They would greatly increase the probability that insurance would cover the medications to lose weight.
The company announced earlier this year that a phase 3 study revealed that the Patients with type 2 diabetes lost almost 8% of your body weight after 40 weeks of treatment with orforglipron.
Lilly has declared that he has begun to manufacture the drug to accumulate stocks before its commercial launchwhich should help avoid experienced scarcity when the initial demand for injectables exceeded supply.
The Complete rehearsal results backed by Lilly will appear next month in an important EUROPE MEETINGA over diabetes, according to Indianapolis headquarters.
Source: Ambito
I am a 24-year-old writer and journalist who has been working in the news industry for the past two years. I write primarily about market news, so if you’re looking for insights into what’s going on in the stock market or economic indicators, you’ve come to the right place. I also dabble in writing articles on lifestyle trends and pop culture news.
